Overview

LMWH to Prevent Preeclampsia and Fetal Growth Restriction

Status:
Terminated
Trial end date:
2003-12-01
Target enrollment:
0
Participant gender:
Female
Summary
The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both.
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Florence
Treatments:
Dalteparin
Heparin
Heparin, Low-Molecular-Weight
Tinzaparin
Criteria
Inclusion Criteria:

- Previous severe preeclampsia

- Previous severe fetal growth restriction

- Heterozygous Factor V Leiden

- Heterozygous G20210A prothrombin gene mutations

Exclusion Criteria:

- renal disease

- chronic hypertension

- preexisting diabetes mellitus

- homozygosity for Factor V Leiden

- homozygosity for prothrombin G20210A mutation

- hyperhomocysteinemia

- protein C deficency

- protein S deficency

- antithrombin deficiency

- positive anticardiolipin antibodies

- positive lupus anticoagulant